Elsevier

Brain Research

Volume 636, Issue 1, 4 February 1994, Pages 1-8
Brain Research

Mu-Opioid receptors modulate noradrenaline release from the rat hippocampus as measured by brain microdialysis

https://doi.org/10.1016/0006-8993(94)90169-4Get rights and content

Abstract

The modulation of noradrenaline (NA) release via presynaptic opioid receptors in the hippocampus of freely moving rats was studied by the use of brain microdialysis. Extracellular levels of NA were estimated by assaying its concentrations in the perfusion fluid using high-performance liquid chromatography (HPLC) with electrochemical detection (ECD). Spontaneous NA levels were reduced by tetrodotoxin (1 μM) co-perfusion and were increased by peripheral administration of desipramine (5 and 10 mg/kg, i.p.). Addition of potassium (K+, 60 and 120 mM) to the perfusion fluid evoked a concentration-dependent release of NA. K+ (120 mM)-evoked NA release was markedly reduced by removal of calcium (Ca2+) from the perfusion fluid. These results indicate that both the spontaneous and the K+-evoked NA release measured by the use of brain microdialysis coupled with HPLC-ECD can be used as indices of neuronal release from the noradrenergic nerve terminals. A μ-opioid receptor agonist, morphine (0.01–10 μM), when co-perfused with K+ (120 mM), produced a reduction of K+-evoked NA release in a concentration-dependent manner. Neither co-perfusion with a high concentration of [d-Pen2,d-Pen5]-enkephalin (DPDPE) (10 μM), an agonist selective for δ-opioid receptors, nor with U-69593 (10 μM), an agonist selective for κ-opioid receptors, modified the K+ (120 mM)-evoked release of NA. Morphine-induced (1 μM) inhibition of NA release was blocked by a μ-opioid receptor antagonist, naltrexone (3 and 9 mg/kg, i.p). Naltrexone by itself did not alter the spontaneous NA levels or the K+-evoked NA release. The morphine-induced (1 μM) inhibition of NA release was abolished by pretreatment with pertussis toxin (PTX) that was perfused into the hippocampus by push-pull cannulation. These findings suggest that NA release is functionally modulated via the μ-opioid receptors located on noradrenergic nerve terminals in the rat hippocampus. It indicates, furthermore, the possibility that the inhibition of NA release via the μ-opioid receptors is linked to G-proteins which are substrates of PTX.

References (35)

  • StinusL. et al.

    Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal

    Neuroscience

    (1990)
  • WerlingL.L. et al.

    Opioid receptor regulation of the release of norepinephrine in brain

    Neuropharmacology

    (1987)
  • YoshiokaM. et al.

    Opioid receptor regulation of 5-hydroxytryptamine release from the rat hippocampus measured by in vivo microdialysis

    Brain Res.

    (1993)
  • ArbillaS. et al.

    Morphine and beta endorphin inhibit release of noradrenaline from cerebral cortex but not of dopamine from rat striatum

    Nature

    (1978)
  • AttilaL.M.J. et al.

    Acceleration of cerebral noradrenaline turnover after morphine withdrawal and its retardation by acute morphine administration in rats

    Naunyn-Schmiedeberg's Arch. Pharmacol.

    (1984)
  • BadoerE. et al.

    The K+-induced increases in noradrenaline and dopamine release are accompanied by reductions in the release of their intraneuronal metabolites from the rat anterior hypothalamus

    Naunyn-Schmiedeberg's Arch. Pharmacol.

    (1989)
  • CrainB.J. et al.

    Quantitative autoradiographic analysis of mu and delta opioid binding sites in the rat hippocampal formation

    J. Comp. Neurol.

    (1986)
  • Cited by (30)

    • Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens

      2008, Neuropharmacology
      Citation Excerpt :

      In order to minimize the concentration gradient around the probe and, therefore, to maximize the anatomical specificity of the pharmacological treatments (i.e. to reduce the possibility of diffusion at significant concentrations at distant sites to the analyzed subregion), we selected the lowest dose of these opioid drugs that, in preliminary experiments, produced a significant effect on DA levels. These low doses were equal to, or somewhat lower than, those used in other studies (Dourmap et al., 1997; Matsumoto et al., 1994; Piepponen et al., 1999; Yokoo et al., 1994; Yoshioka et al., 1993). After the 20 min period of retrodialysis application of the drugs, the experiments were continued over an additional period of 100 min.

    • Influence of glial cells in the dopamine releasing effect resulting from the stimulation of striatal δ-opioid receptors

      2007, Neuroscience
      Citation Excerpt :

      Moreover, this indicates that the dopamine release, although modulated by glutamate, could be maintained at the same level despite the disruption of glutamatergic transmission. The present results confirm previous experiments (Dourmap et al., 1991; Matsumoto et al., 1994; Billet et al., 2004) showing that the selective δ-opioid receptor agonist DPDPE (Mosberg et al., 1983) increases both glutamate and dopamine dialysate levels in the striatum via δ-opioid receptors (Schad et al., 1996; Billet et al., 2004). The local infusion of l-αAA into the striatum increased significantly, 20 min later, both glutamate and dopamine dialysate levels.

    • Knockout of the mu opioid receptor enhances the survival of adult-generated hippocampal granule cell neurons

      2007, Neuroscience
      Citation Excerpt :

      Indirectly, MOR could regulate neurogenesis by altering the levels of pro-survival factors in the dentate gyrus. MOR activity has been shown to be involved in the regulation of a number of neurotransmitters in the hippocampus including acetylcholine (ACh, Lapchak et al., 1989; Kaplan et al., 2004), GABA (Drake and Milner, 1999, 2002; Akaishi et al., 2000), and norepinephrine (NE, Matsumoto et al., 1994). GABA modulates neurogenesis, but appears to do so by altering cell differentiation, not survival (Tozuka et al., 2005; Karten et al., 2006).

    • Opioid systems in the dentate gyrus

      2007, Progress in Brain Research
      Citation Excerpt :

      Opioids cause presynaptic inhibition of certain subcortical afferents to the DG. Neurochemical measures of transmitter release showed that the stimulated release of serotonin (Yoshioka et al., 1993), norepinephrine (Jackisch et al., 1984; Matsumoto et al., 1994), and acetylcholine (Jackisch et al., 1986) were each directly inhibited by opioid receptor activation. The ionic mechanisms of these inhibitory presynaptic actions have not been directly defined because it is difficult to electrophysiologically record from hippocampal nerve terminals, but molecular mechanisms that have been suggested include activation of delayed rectifying potassium channels (Wimpey and Chavkin, 1991), opioid inhibition of voltage-sensitive calcium channels by Gβγ binding (Herlitze et al., 1996; Ikeda, 1996), or direct inhibition of the vesicular fusion machinery by opioid receptor activation (Scholz and Miller, 1992; Capogna et al., 1996).

    View all citing articles on Scopus
    View full text